Glenmark Pharmaceuticals Limited — Financials & Forensics

Sector: Healthcare · NSE: GLENMARK · BSE: 532296 · ISIN: INE935A01035

₹2,366.40

Closing price
08 May 2026

+43.1%

1-year price change

₹66,773 Cr

Market cap

63.8×

P/E ratio (trailing)

12.5%

Return on Equity (FY)

0.11%

Dividend yield

FY25 headline numbers

Line item	FY25
Revenue from operations	₹13,322 Cr
EBITDA	₹1,979 Cr
EBITDA margin	14.8%
Profit after tax	₹1,047 Cr

Source: Glenmark Pharmaceuticals Limited's FY25 regulatory filing under SEBI LODR Regulation 33.

Deeper analysis

See Glenmark Pharmaceuticals Limited's full quarterly & annual history

Last 20 quarters of P&L · 7-year balance sheet · cash flow · shareholding pattern · concall transcripts & audio summaries · insider-trade history · bulk & block deals — all behind a free sign-up.

About Glenmark Pharmaceuticals Limited on Indian Stock Alerts

Indian Stock Alerts tracks Glenmark Pharmaceuticals Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.

Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.

Important. All data on this page is sourced from Glenmark Pharmaceuticals Limited's own public regulatory filings under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Investors should consult registered advisers before making investment decisions.